世界衛生組織（WHO）於 2026 年 2 月 27 日正式公布 2026–2027 北半球流感疫苗組成建議。此次更新重點涵蓋兩大關鍵發展：A(H3N2) 亞演化支（subclade）K 的持續擴散，以及 B/Victoria 譜系（lineage）新病毒株日益增加的流行趨勢。
為支援疫苗開發研究，Sino Biological 已同步推出 2026-2027 流感疫苗株之重組抗原（recombinant antigens）。
關鍵研究資源：ProVir® 病毒抗原庫
Sino Biological 擁有全球規模最大的病毒抗原收藏庫 ProVir®，提供一系列重組流感抗原產品，涵蓋近年來所有 WHO 推薦疫苗株的關鍵蛋白：
血球凝集素（Hemagglutinin, HA）
神經胺酸酶（Neuraminidase, NA）
核蛋白（Nucleoprotein, NP）
請參考以下:
|
|
|
|
Antigens for
2026-2027
Influenza Vaccine
Strains Covering HA Trimer, NA, and NP
|
|
|
|
On February 27th, 2026, the World Health Organization (WHO) announced its 2026–2027 Northern Hemisphere influenza vaccine composition. The update highlights two key developments: the continued spread of A(H3N2) subclade K and the growing circulation of new B/Victoria lineage strains. To support vaccine research, Sino Biological has released the recombinant antigens for 2026-2027 influenza vaccine strains.
|
|
With the world’s largest viral antigen collection, ProVir®, Sino Biological provides a range of recombinant influenza antigen products, including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. Learn More >>>
|
|
|
|
Antigens for 2026-2027 Northern Hemisphere Influenza Vaccine Strains
|
|
A/Missouri/11/2025 (H1N1)
|
|
|
A/Darwin/1454/2025 (H3N2)
|
|
Recommended for Egg-based, Cell culture-, recombinant protein- or nucleic acid-based (trivalent) Vaccine
|
Recommended for Egg-based, Cell culture-, recombinant protein- or nucleic acid-based (trivalent) Vaccine
|
|
HA: 41105-V08H
|
HA: 41128-V08H
|
|
NA: 41106-V08B
|
NA: 41151-V08B (pre-order)
|
|
NP: 41107-V08B
|
|
|
|
Featured Influenza A Antigens
|
|
Influenza A H1N1 (A/Missouri/11/2025) HA Trimer Protein (His Tag) | Cat#: 41105-V08H
|
|
MALS-Validated Purity & Structure
|
|
|
|
High Purity: ≥ 90% as determined by SDS-PAGE & SEC-MALS.
Native State: MALS-verified HA trimer with a molecular weight of 226.7 kDa.
|
|
Superior Bioactivity
|
|
|
|
High Sensitivity: Robust binding to Anti-HA (CR9114) with an EC50 of 0.2-2 ng/mL.
QC Tested: Guaranteed performance for your neutralizing assays
|
|
|
|
|
|
|
|
|
Don’t Miss Out!
|
|
Kinase Drug Discovery Solutions >>
|
|
Center for Bioprocessing (C4B)
US-Based Recombinant Production >>
|
|
|
|
|
|
|
